Legal status · Record reviewed
Ipamorelin has no single legal status. It depends on the product and how it is supplied.
Still being studied; no FDA-approved product identified. A research use only label does not make a product approved for people.
Pharmacy mixing (compounding): FDA lists it in Category 2 for possible safety risks (FDA page dated April 22, 2026).
Sports: the anti-doping rules we checked list it as prohibited (checked July 23, 2026).
Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Whether you may buy, sell, or use a product also depends on pharmacy (compounding) rules, a prescription, and state law. Read how U.S. peptide law works.
Have a product in hand? Check if it is a prescription, compounded, or research-only product.
No FDA-approved product
The record found no FDA-approved product. A label that says research use only does not make a product approved for people.
What the record says: Still being studied; no FDA-approved product identified
Category 2: safety risk
Listed as ipamorelin acetate under the 503B policy. A separate nomination was withdrawn.
FDA placed it here because it may present significant safety risks in compounding, pending further review. Each entry names the policy it falls under: 503A covers pharmacies, and 503B covers outsourcing facilities.
Source: FDA's page of bulk drug substances that may present significant safety risks. FDA marks it current as of . We checked it on .
Prohibited
Growth-hormone secretagogues and mimetics are prohibited under the current WADA framework.
Checked . Read the rule we checked. Check the current World Anti-Doping Agency list and your sport's rules before you compete.
Other names in this record: ipamorelin acetate, NNC 26-0161, growth hormone secretagogue.
What it is, what studies in people show, and what is still unknown.
Open the Ipamorelin recordSee the FDA, compounding, and sports status of every peptide we reviewed in one table.
See all 34 peptides